RXADVANCE
2 Park Central Drive
Southborough, MA 01772

FIRST TIME GENERIC APPROVAL

Brand Name	Butrans®
Generic Name	buprenorphine transdermal system
Drug Manufacturer	Amneal Pharmaceuticals LLC

New Drug Approval

Dosage form(s): 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr, and 20 mcg/hr Transdermal System
Therapeutic equivalent code: AB

FDA Approval Date: April 14, 2020

Indications for Use

buprenorphine transdermal system is indicated for:

- Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

© RxAdvance Corporation. Confidential and Proprietary.